Takeda Canada Inc. ("Takeda") is pleased to announce that it has completed negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) for a Letter of Intent (LOI) for LIVTENCITY® (maribavir) for the treatment for adults with a post-transplant cytomegalovirus (CMV) infection/disease who are refractory (with or without genotypic resistance) to one or more prior antiviral therapies.1 With the LOI stage now complete, the provinces and territories may proceed in initiating their individual processes of listing LIVTENCITY as part of their formularies.
Takeda Canada Inc. Concludes Letter of Intent (LOI) with the Pan-Canadian Pharmaceutical Alliance (pCPA) for LIVTENCITY (Maribavir) for the Treatment of Adults with a Post-Transplant Cytomegalovirus (CMV) Infection
Company Profile
Thu. 16 May 2024, 8:04am ET
Benzinga
News